Valeant Pharmaceuticals International, Inc. (VRX) During the most recent session, the shares traded at 0.1 points or 0.86% higher at $11.11. The money flow data is unimpressive with the net money flow value of $(-1.94) million. As per the intraday data, the upticks measured $17.59 million and the downticks measured $19.53 million. As a result, the up/down ratio registered a value of 0.9. The shares have seen -9.27% price change for the week.A block trade also made an entry with $1.98 million flowing in through upticks while $4.25 million flew out through downticks. The block tradeoff had the up/down ratio of 0.47. The net money flow for this big transaction was $(-2.27) million.
Based on the Stock Research reports from financial advisors, there are 2 Analysts recommending as a Strong Buy, Investors should also note that 9 Stock brokerage firms are recommending to Hold the stock for short term. There are 3 Analysts recommending as a Strong Sell. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rose 1.73% or 0.19 points on Thursday and made its way into the gainers of the day. After trading began at $11.08 the stock was seen hitting $11.33 as a peak level and $10.9 as the lowest level. The stock ended up at $11.2. The daily volume was measured at 19,762,965 shares. The 52-week high of the share price is $38.5 and the 52-week low is $10.5. The company has a market cap of $3,896 million.
According to the corporate earnings calendar, Valeant Pharmaceuticals International, Inc. will release next earnings on Jun 06, 2017 with an estimated EPS consensus of $0.99. Based on the consensus of stock financial advisors the stock has a price target of $22.09. Current year estimate on EPS consensus is $3.98. The Estimated EPS rate for Long term growth is $14.3. For Dividend Investing Stock Market Traders Valeant Pharmaceuticals International, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0. It has a Payout Ratio of 0 and the change in Dividend payout ratio is 0.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeants development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.